Drug Profile

QEL 003

Alternative Names: QEL-003

Latest Information Update: 19 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quell Therapeutics
Developer AstraZeneca; Quell Therapeutics
Class Anti-inflammatories; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Jun 2025 AstraZeneca exercises its exclusive option to license the potential therapy for further development and commercialization
07 Mar 2025 Preclinical trials in Inflammatory bowel diseases in United Kingdom (Parenteral) (Quell Therapeutics pipeline, March 2025)
09 Jun 2023 Quell Therapeutics and AstraZeneca entered into a collaboration, exclusive option and license agreement for CAR-T regulatory cell therapy in Type 1 diabetes mellitus and Inflammatory bowel diseases

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com